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Abstract: The Protoparvovirus (PtPV) genus of the Parvoviridae family of viruses includes important
animal pathogens and reference molecular models for the entire family. Some virus members of
the PtPV genus have arisen as promising tools to treat tumoral processes, as they exhibit marked
oncotropism and oncolytic activities while being nonpathogenic for humans. The PtPVs invade and
replicate within the nucleus making extensive use of the transport, transcription and replication
machineries of the host cells. In order to reach the nucleus, PtPVs need to cross over several
intracellular barriers and traffic through different cell compartments, which limit their infection
efficiency. In this review we summarize molecular interactions, capsid structural transitions and
hijacking of cellular processes, by which the PtPVs enter and deliver their single-stranded DNA
genome into the host cell nucleus. Understanding mechanisms that govern the complex PtPV entry
will be instrumental in developing approaches to boost their anticancer therapeutic potential and
improving their safety profile.
Keywords: parvovirus; Protoparvovirus; icosahedral capsid; receptor binding; capsid rearrangements;
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1. Introduction
The Parvoviridae is a family of small, non-enveloped, icosahedral viruses with linear
single-stranded genomes, infecting an exceptionally wide range of animal hosts, from invertebrates
to mammals, including humans. Currently, species within the genus Protoparvovirus (PtPV) of
the Parvoviridae include [1]: Rodent protoparvovirus 1 (H-1 parvovirus; H-1PV, Kilham rat virus,
LuIII virus, minute virus of mice (MVM), mouse parvovirus, tumor virus X, rat minute virus);
Rodent protoparvovirus 2 (rat parvovirus 1); Carnivore protoparvovirus 1 (canine parvovirus (CPV) and
feline panleukopenia parvovirus (FPV)); Primate protoparvovirus 1 (bufavirus) and Ungulate parvovirus 1
(porcine parvovirus (PPV)). The diseases caused by PtPVs in their natural hosts range in severity
from subclinical to lethal infections, depending on the virus and host factors such as age,
immune-competence and health conditions [2].
The PtPV single-stranded DNA (ssDNA) genome, of approximately 5 kb in length, is organized
in two open reading frames, a non-structural (NS) and a structural (VP) [3]. Structure and biophysical
properties of PtPV capsids are of paramount importance to prevail in nature and enter their host cells.
The parvovirus capsid is a 25 nm-diameter assembly of 60 subunits in a T = 1 icosahedral symmetry
of two to four largely overlapping proteins commonly designated VP1 to VP4 [4]. The 3-D atomic
structure of PtPV capsid is available for some virus members (e.g., [5–7]). Common features are the
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folding of their protein subunits into an eight-stranded antiparallel β-barrel topology, a β-cylindrical
projection encircled by a canyon-like depression that surrounds the fivefold symmetry axes, and a pore
at the center of the β-cylinder running between the surface and the interior of the capsid. The topology
of the capsid surface differs among the parvoviruses conferring characteristic virus host range. Flexible
domains in the capsid are the N-terminal sequences of the VP subunits, which are dispensable for
virus assembly, but strictly required for infection, as they contain functional motifs that can be hidden
or exposed on the capsid surface at specific host cell compartments to mediate virus entry [8–11] and
egress [12].
The biological relevance of PtPVs is not only due to their pathogenicity in their natural host,
but also because some rodent PtPVs, such as H-1PV, MVM and LuIII, display natural oncotropism
and marked oncolytic activities against human cancer cells, while being non-pathogenic for humans.
Parvovirus replication is strongly dependent on host cell factors expressed during the S-phase, due
to the limited coding capacity of the genome and their inability to induce resting cells to enter
S-phase [13,14]. Moreover, the virus cycle, particularly nuclear translocation of the structural subunits
and capsid assembly, are tightly coupled to the cycle of the host cell [15]. The dependency of PtPVs on
transformed-dependent factors [16–19] contributes to the high susceptibility of certain human tumor
cells to PtPV-induced cell killing. Therefore, these features, and the low prevalence of pre-existing
antibodies, make the group of rodent PtPV viruses promising tools to treat human tumors [20].
During the entry process, the robust PtPV virion must undergo defined structural changes and
overcome numerous host cell barriers to successfully traffic from the cell surface to the nucleus for
genome delivery. Indeed, most of the incoming virions fail to follow this complex infectious route,
accounting for the high particle-to-infectious ratio typically observed for PtPV infections. Therefore,
productive and non-productive pathways are intermingled and hard to distinguish, which complicates
the identification of the critical mechanisms leading to a productive infection. Nevertheless, the major
steps of the entry process can be drawn faithfully. PtPVs enter the cells through receptor-mediated
endocytosis using a wide variety of receptors, which explains their differences in tropism and
pathogenesis. Subsequent to virus internalization, PtPVs enter the endocytic route. However,
the timing of virus trafficking through the endosomal pathway, the cellular elements involved and
the site of endosomal escape into the cytosol, vary considerably among virus species and host cells.
Following endosomal escape a small subset of virions is transported to the nuclear vicinity, where
delivery of the genome into the host nucleus takes place by as yet poorly characterized mechanisms.
This review is focused on the virus–host cell interactions involved during PtPV entry. The reader is
referred to previous reviews on this issue [21–24]. Here, we have updated and summarized our current
knowledge, and further discussed new aspects on entry mechanisms not previously covered. Starting
from the initial interaction with host cell receptors, we guide through the sequential steps leading to
delivery of the PtPV genome into the nucleus. The review is intended to provide a comprehensive
view of the diversity of processes implicated in PtPV entry, including virus-cell interactions, sequential
exposure of structural protein domains and capsid rearrangements. A detailed understanding of
the molecular mechanisms underlying these processes will be pivotal to the rational design of PtPV
vectors with enhanced cell entry properties, to establish efficient therapies against pathogenic PtPV
for their control in nature, and to develop innovative PtPV-based anticancer therapies with improved
efficiency and safety.
2. Functional Receptors for Protoparvovirus Entry
The initial interaction of parvoviruses with the host cell occurs upon binding to a specific receptor
exposed on the host cell membrane. Recognition of cell surface molecules enables the first step of
infection, and hence, represents a key parameter of tropism and pathogenesis. To date, different
receptor biomolecules, such as proteins and carbohydrates with specific virus-binding properties,
have been identified as attachment factors and, in some cases, as functional receptors for members of
the PtPV genus. One of the best studied example is represented by the interaction of the transferrin
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receptor (TfR) with CPV and FPV. Both viruses use TfR to bind and infect cells, as the susceptibility to
these viruses requires the constitutive or transient expression of the TfR [25]. Binding to TfR correlates
with host specificity of these viruses, as FPV binds the feline TfR only, while CPV binds both the canine
and feline TfRs. CPV variants accumulated changes on the top and side of the three-fold spike of the
capsid surface, which confer more efficient use of the canine TfR receptor and reduce binding to the
feline TfR [26,27].
The receptor residues involved in CPV-specific binding localize to the TfR apical domain,
and substitution of single amino acids may shift TfR binding ability to CPV or FPV [28,29]. The TfR
molecules asymmetrically associated in vitro with a few of the sixty icosahedral equivalent binding
sites on the CPV capsid near the three-fold axis of symmetry, Figure 1a. Importantly, the pattern of
TfR-CPV capsid interaction was compromised by alteration of key residues of both the receptor and
the virus capsid binding domain [30] such as mutations at residues 206–380 of the TfR apical domain
which reduce binding to CPV capsids. In particular, the N-linked glycosylation site at position 384
in the canine TfR provided resistance to the carnivore parvoviruses circulating prior to about 1975,
when a variant virus emerged that overcame this block [31]. The use of TfR receptors by CPV and FPV
variants illustrates the capacity of PtPV to adapt to receptors determining host range.
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Figure 1. Structures of receptor-Protoparvovirus capsid complexes: (a) Asymmetric binding of
transferrin receptor (TfR) to the CPV capsid. The image illustrates a TfR dimer manually fitted
into the cryoEM density of CPV capsid. The interaction is best resolved between one of the two apical
domains of the TfR dimer (green) and the shoulder of a spike near a three-fold icosahedral axis of the
CPV capsid. (Reproduced with ermission from Hafenstein, S. et al. [32]); (b,c) X-ray crystal structure
identifying an infectious receptor attachment site on a PtPV capsid at high resolution: MVMp capsids
soaked wi h si lic acid showing the electron density of the carbon backbone allocat d in the twofold
pocket adjacent to the I362 and K368 residues determining in vivo pathogenicity in severely combined
immunodeficient (scid) mice. (Reproduced with ASM permission from Lopez-Bueno et al. [33]).
Sialic acid (SA; N-acetylneuraminic acid) glycan isanother well-characterized PtPV receptor,
which is probably the most commonly used in nature. Glyca s represent ajor cell surface
carbohydrate components, thereby providing a vast coll ctio of cellular attachment factors for
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many viruses [34]. Biochemical studies have shown SA to serve as a common primary attachment
factor for several PtPV. However, it is important to distinguish between unspecific attachment of
parvoviral capsids to SA on multiple cell surfaces, and the functional interactions where SA acts as
a receptor leading to the infection of permissive cells. For example, in vitro hemagglutination assays
revealed that CPV and FPV bind to erythrocytes through SA, however the biological significance in
the natural host infection, which is mediated by the TfRs (see above), remains unclear [35]. Similarly,
the biological role(s) in the natural infection of the observed bovine parvovirus (BPV) binding to
sialylated glycoproteins on erythrocyte and nucleated cell membranes [36–38] require further research.
SA was first suggested to play a role in MVM binding to cell surfaces [3]. The virus binding sites
per cell were in the range of 4–8 × 105 SA molecules in established cell lines [39,40] and primary
host cells [41]. Subsequently, it was demonstrated in cell culture experiments that indeed SA acts
as functional receptor for the infection of several PtPV species, including MVM [33], PPV [42] and
H1-PV [43].
PtPV/SA recognition plays a major role in the emergence of virulent viruses in vivo, as it
was exemplified in adult severely combined immunodeficient (scid) mice infected by different
MVM strains. The virulent immunosuppressive strain (MVMi) caused a severe leukopenia with
deregulated erythropoiesis [44], whereas infections with the prototype MVM strain (MVMp) remained
asymptomatic over several weeks [33]. However, upon eight weeks post-infection, lethal MVMp
genetic variants emerged which carried only one of the three single amino acid changes (V325M,
I362S, K368R) in the common sequence of their structural proteins. These mutations conferred lower
capsid binding affinity to SA components of the natural receptor [33,41]. The substituted amino acid
residues localize within a dimple depression at the icosahedral two-fold axis of symmetry in the MVM
capsid, Figure 1b, and establish direct contact with the SA molecule, highlighting their role as crucial
determinants of MVM in vivo pathogenicity and adaptation to the hosts.
Binding to an array of glycans enabled identification of SA types recognized by the two natural
MVM strains, as well as by the emerged virulent capsid variants [45], and supported the evidences
that lower affinity to SA glycans, rather than a different SA receptor specificity, determines MVM
virulence. However, it remains unclear how capsid binding to SA-glycans may determine MVM
tropism in vitro and in mice. Tropism determinants of MVMp and MVMi capsids in vitro mapped to
a few residues which also localized to the two-fold dimple [46–49]. However, the N- and O-glycans
and polar glycolipids composition of the cell lines used in those studies failed to explain MVM
tropism solely based on the SA cell surface composition [50], suggesting the requirement of other
cellular factors. MVMp undergoes a remarkable switch of tropism from asymptomatic fibrotropic
to pathogenic hematotropic behavior upon weeks post- infection in scid mice [51]. This dramatic
change in pathogenicity involved the emergence of a heterogeneous viral population harboring
multiple genetic changes, which were strictly confined to the surface of the dimple surrounding the
SA-receptor binding pocket [51]. Therefore, the capsid residues mediating direct contact with SA are
major determinants of MVM virulence and tropism along its evolution in mice. Further research will
be required to elucidate whether these genetically heterogeneous variants co-operate to cause disease,
use different SA molecules to infect distinct hematopoietic precursors, or arise in naturally infected
host settings.
3. Uptake into Host Cells
PtPVs are internalized by host cell receptor-mediated endocytosis upon binding to the functional
receptor [22,23,52]. The endocytic route offers numerous advantages for the karyophilic parvoviruses.
Endosomes may not only delay the detection of the incoming viral ssDNA by cellular sensors of
innate immunity, but also provide a rapid and efficient transport towards the nuclear periphery,
circumventing the viscous cytoplasm, where molecular crowding and the mesh-like structure of the
cytoskeleton strongly hinder the mobility of macromolecules [53]. Exposure of incoming viruses to
dynamic changes of the endocytic environment provides the triggers necessary to initiate the infection.
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The unique endolysosomal microenvironment differs considerably from the extracellular milieu [54].
The increasing acidic environment, changes in redox conditions and acid proteases and phosphatases,
enable the capsids to undergo structural conformational changes required for the subsequent step of
the infection, the endosomal escape.
There are distinct pinocytic pathways by which physiological cargo, as well as viral particles,
can be taken into host cells. Clathrin- and caveolae-mediated endocytosis are two dynamin-dependent
pathways. Macropinocytosis, lipid-raft mediated and the caveolin/clathrin-independent endocytosis
are dynamin-independent pathways [55,56]. Clathrin-mediated endocytosis (CME) is the most
common mechanism for endocytosis of small viruses and represents the default internalization
route employed by parvoviruses [42,52,57–59]. A clathrin endocytic structure initiates upon clathrin
recruitment to the plasma membrane by AP2 adaptor complexes. Clathrin forms a triskelion by the
assembly of three heavy and three light chains to finally form a three-dimensional polygonal lattice,
leading to progressive invagination of the plasma membrane into a clathrin-coated pit. Dynamin
self-assembles at the neck of the coated pit and forms a collar-like structure that pinches off the
clathrin-coated vesicle from the plasma membrane. The newly formed vesicle becomes rapidly
uncoated and delivers its viral cargo by fusing with an early endosomal vesicle at the periphery of the
cell [60].
Recent research has demonstrated that, in addition to the classical CME, PtPV may use several
alternative endocytic routes. For example, PPV utilizes macropinocytosis [42] as additional uptake
mechanism. CPV and FPV use TfR for uptake, which is typically endocytosed by CME. However,
altering or removing the internalization signal of TfR delays uptake, but does not prevent infection [27],
suggesting the existence of alternative uptake mechanisms. Most recently, it has been shown
that MVMp enters its host cell by at least three potential endocytic routes [61]. Inhibition of
various endocytic pathways with specific drugs in combination with electron microscopy (EM),
immunofluorescence (IF) microscopy, and fluorescence-activated cell sorting (FACS), identified various
endocytic pathways for MVM mediated by clathrin, caveolin, and clathrin-independent carriers
(CLIC).However, the latter endocytic uptake mechanism was restricted to transformed cells only and
did not occur in murine A9 fibroblasts. This observation was confirmed in further experiments which
demonstrated that the dynamin inhibitor dynasore completely blocked MVM uptake in A9 mouse
fibroblasts, whereas its inhibitory effect was incomplete in transformed cells [61]. These results indicate
that both clathrin- and caveolin-mediated MVM endocytosis is dependent on dynamin in murine
A9 fibroblasts, but transformed cells allow dynamin-independent CLIC-mediated uptake of MVMp.
These observations imply that although internalization by clathrin might represent the main entry
route of PtPV, other alternative routes of uptake might be involved in parallel or in certain cells.
Viruses have evolved different strategies to promote their internalization into host cells. Some
viruses bind their cognate receptor(s) and remain immobile until they are endocytosed. Others,
after binding their corresponding receptor will diffuse laterally at the cell surface seeking additional
receptor molecules and inducing clustering of receptors prior to internalization. Following lateral
diffusion along the plasma membrane, some particles are captured into preexisting or forming
clathrin-coated areas, while others induce clathrin assembly at the site of binding [62,63]. Although
the receptors utilized by some PtPVs have been defined in detail, the dynamics of virus-receptor(s)
complex formation and the subsequent signaling cascade that triggers the uptake process remain
poorly understood. The dynamics of the uptake process of PtPV have been best characterized for
CPV. Upon binding to a limited number of TfRs, CPV capsids quickly diffuse laterally on the plasma
membrane until they become captured by a forming clathrin coated pit [64]. The authors found
a correlation between the number of receptors attached to a virus particle during lateral diffusion and
the endocytic rate of these particles. Due to the low affinity of the virus capsids to TfR, the capsids can
only diffuse during a short period of time on the cell surface. If not quickly captured by a pre-assembled
clathrin coated pit, the capsids dissociate from its receptor. At present, it is not clear whether rodent
PtPVs follow a similar uptake process involving lateral diffusion and capture by pre-existing clathrin
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structures. It is also unknown whether rodent PtPVs are readily internalized following the interaction
with a single receptor, mainly SA, or require interactions with an additional receptor(s) to initiate the
uptake process.
The oncotropism of rodent PtPV is influenced by multiple factors acting at different infection
steps. It has recently been shown that one of those factors is an enhanced virus uptake in cancer
cells. Cell migration, which is typically associated with some aggressive cancer cells, promotes MVMp
uptake [65]. Another finding establishing a correlation between MVMp uptake and cancer cells is
the requirement of MVMp for galectin-3, a multifunctional protein implicated in cancer metastasis.
Galectin-3 may modulate clustering and signaling activity of the MVM receptor stimulating the uptake
of the virus [66]. These results emphasize that, apart from factors occurring late during the infection,
early events of the infection also contribute to the oncotropism of these viruses.
4. Endosomal Trafficking and Capsid Rearrangements
Endosomal trafficking of PtPV virions is thought to be a slow and rate-limiting process in
viral infection [67]. The special endolysosomal microenvironment triggers crucial capsid structural
rearrangements. For instance, MVM has been reported to traffic slowly through the endocytic pathway
and only reaches the cell nucleus after 8 h post infection (hpi) when DNA replication was detected [68].
Several lines of evidence confirm that endosomal processing of incoming PtPV particles is essential.
For CPV, capsids pre-treated at low pH were unable to accumulate in the nucleus following cytoplasmic
injection [69]. For MVM, the structural rearrangements were equally impaired by lysosomotropic
drugs, thereby preventing infection [67,68]. These drugs, such as bafilomycin A1 or the weak base
chloroquine diphosphate, raise the endosomal pH by inhibiting the vacuolar-type H+ -adenosine
triphosphatase (ATPase) [70,71], or by accumulating inside acidic compartments [72], respectively.
Endosomal acidification has been demonstrated to be essential for the infection of CPV [57,69,73],
MVM [67,68], as well as other parvoviruses.
The major rearrangements that PtPV capsids undertake along entry can be traced by the
configuration and functions of the N-terminal sequences of the VP1 and VP2 subunits. The amino
termini of VP1 (VP1-Nt, 1Nt or VP1uR) and VP2 (VP2-Nt or 2Nt) are flexible domains whose
configuration cannot be resolved in the X-ray crystal structure of PtPV capsids [5–7], and are normally
concealed in their interior. These sequences carry essential transport signals and are thought to
translocate across the five-fold channel of the capsid. This led to the suggestion that VP N-termini
act as drivers of the traffic of intact virions across the cellular compartments along the virus life
cycle [12]. Disparate roles for these sequences along the entry of the virion inside the cell were first
indirectly suggested as VP2 was found necessary for capsid assembly, but VP1 was essential for
infectivity [74]. For VP1 this activity resided in functional domains of its unique terminal sequences
(VP1uR), which included clusters of basic amino acids (BC1 to BC4) conserved in many parvoviruses [9],
as well as other non-basic domains (e.g., PLA2, see below), which play specific roles during the
entry process.
The externalization through the parvovirus fivefold capsid channel has been studied in detail for
the VP2-Nt, as it can be fairly induced in vitro, although harsh conditions may also trigger VP1-Nt
externalization in CPV [21,75], and MVM particles [76,77]. Assays conducted by multiple authors
demonstrated that VP2-Nt externalization can be induced by heat in native capsids and virus like
particles (VLPs), which for MVM share 3-D crystal structure [78]. Acidic treatment of CPV particles
mimicking endosomal pH induced VP1-Nt exposure [79] but in MVM the cleavage of N-VP2 termini
to VP3 was a prerequisite for VP1-Nt externalization [76,80]. VP2-Nt externalization was associated
with a reproducible change in the emission fluorescence of tryptophan residues [81], which are located
at distant positions to the channel [82], implying that heat provokes a wide conformational transition
in the capsid. The dynamic exposure of Nt sequences across the channel is regulated by amino acid
residues lying at the base of the pore [81], some of them configuring a hydrophobic gate tightly
controlling the externalization of VP2-Nt and VP1 Nt sequences [80,83,84].
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It is controversial to which extent these capsid structural rearrangements observed in vitro do
occur in cells, and whether they play a role at early stages of the infection. Most evidence suggests
that the in vitro treatments cannot recapitulate the complex physiological conditions in cells, implying
that a combination of several factors, including receptor binding, low endosomal pH or interactions
with unknown host proteins, are relevant for these structural transitions. However, in a few cases the
in vivo observations support at least some of the in vitro structural changes. For example, as early as
30 min after endocytosis, the structural rearrangements of the MVM capsid allowed the cleavage of the
exposed VP2-Nt, and the externalization of originally sequestered VP1-Nt, without the loss of capsid
integrity [67].
The complexity of the functions mediated by VP1-Nt and VP2-Nt during parvovirus entry is
illustrated by the elusive role of the VP2-Nt in this process. The VP2-Nt domain may be cleaved
in vitro to form the VP3 protein by a chymotrypsin-like protease [85–88]. In vivo, the VP2 to VP3
parvoviral cleavage is not a proteolytic maturation event as found in other non-enveloped viruses
(e.g., Poliovirus [89]). It rather occurs in the pH-dependent entry pathway [24,42,68,75], soon after PtPV
internalization [67]. Whether this cleavage plays any role in the infection was unclear since it could not
be prevented by mutagenesis [86] or protease inhibitors [23]. Further, viral stocks exhibiting variable
VP2/VP3 ratios [85,90] or even lacking VP3 subunits [12] were equally infectious. The genetic insertion
of an exogenous peptide at VP2-Nt, however, inhibited VP2 cleavage and MVM infectivity, and it
showed that neither VP3 nor VP1 subunits can accomplish the essential entry function(s) harbored
by the VP2-Nt domain [91]. Although the exact role of the VP2-Nt in virus entry remains uncertain,
an efficient exposure of the VP2 subunits through the channel, which is facilitated by the slender
poly-Gly track [82], and their cleavage inside the cells, were necessary for the infection [91]. Therefore,
we propose a role of the short VP2-Nt sequence on enlarging the functional diameter of the viral
five-fold pore inside the endosome, determining the sequential exposure of VP2-Nt and VP1-Nt in the
incoming metastable PtPV virion, Figure 2.
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subunit anchored by the poly-Gly track is illustrated; (b) Upon receptor-mediated internalization and
low pH exposur inside the endosome, inter al VP2 N-termini access the base of the pore enlarging
the functional diameter of the channel as they bec me extruded to the capsid exterior; (c) Most de
novo expo ed VP2 N-termini are c eaved-off from the capsid surface. The incoming virion traffics
to downstream endosomal compartment(s), with presumed lower protease pools, where the VP1
N-terminus (or 1Nt) is entirely externalized becoming anchored by its poly-Gly track, as the channel
returns to a narrow configuration. 1Nt (or VP1-Nt), the VP1-unique N-terminal sequence (143 amino
acids); 2Nt (or VP2-Nt), the VP2 N-terminal sequence (27 amino acids); GGGG, poly-Glycine track.
Based on references [82,91].
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5. Endosomal Escape
Unlike enveloped viruses, which deliver their genomes into the host cell by fusion with the
plasma or endosomal membranes [92], the non-enveloped viruses must employ alternative strategies
to penetrate, disrupt or breach, the host cell’s delimiting membrane during entry. One of the most
common mechanisms used for this purpose is the proteolytic cleavage of the viral particle [93]. In some
cases an in vitro cleavage by a protease may activate the virus prior to cell inoculation [94], whereas in
other virus systems a lytic peptide with endosomal membrane-interacting activity must be released
from the virion inside the cell for full activity [95,96].
For PtPV the endosomal escape depends on the profound capsid structural rearrangements
occurring inside the endosome (see above), which lead to the externalization of the disordered VP1-Nt.
This VP1 sequence harbours a lipolytic activity to penetrate the endosomal membrane [8]. Evidences
on the capacity of PtPV to permeabilize endosomal membranes came from the progressive release of
labeled dextrans (MW 3 kDa) into the cytosol 8–20 h after co-endocytosis with CPV virions. Larger
dextrans (MW 10 kDa) and α-sarcin were mainly retained in endosomes [57], suggesting incomplete
disintegration of the endosomal membrane.
However, the endosomal escape represents a major barrier for successful PtPV infection. Taking
MVM as an example, a substantial proportion of the incoming MVM virions was demonstrated to
follow a non-infectious pathway ending up in lysosomal compartments where they co-localized with
lysosomal markers [67]. Hence, the endosomal escape represents the major barrier for the subsequent
steps of MVM infection, Figure 3. However, the inability to escape from the endocytic route was not
due to a failure in endosomal processing of MVM since all virions retained in lysosomal compartments
underwent the required structural transitions. MVM VLPs or empty capsids (EC) that accumulated
in lysosomes remained intact up to 50 hpi but the exposed viral DNA of full-virus capsids (FC) was
degraded 21 hpi, most probably by the lysosomal endonuclease DNase II activity [67].
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Figure 3. Accumulation and retention of incoming MVMp inside lysosomes: (a) Immunofluorescence
picture taken 4 h post-infection from a single A9 cell infected with MVMp. Lysosomes are labeled
in red (Lamp1) and viral capsids are labeled in green (B7 Mab) [97]; (b) Electron micrograph taken
18 h post-infection from an A9 cell infected with MVMp. A large amount of incoming viral particles is
retained inside lysosomes.
The mechanism of the PLA2 active domain which is harbored within VP1uR of the PtPV
capsid and mediates endosomal escape has been extensively studied. The VP1-Nt becomes exposed
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in early endocytic vesicles [8,11,67]. Pre-incubation of VP1-Nt exposing CPV virions with PLA2
inhibitors, such as quinacrine and manoalide, significantly reduced or completely abolished infectivity,
respectively [98]. For MVM complementation assays between wild-type and mutant particles have
been used to demonstrate the role of PLA2 in mediating phospholipid bilayer penetration [11].
Accordingly, mutants with amino acid substitutions within their catalytic dyad severely impaired
the enzymatic activity of the lipolytic PLA2, and viral infectivity was completely abrogated.
Polyethyleneimine-induced endosomal rupture or co-infection with wild-type or mutant virions could
partially rescue the mutant phenotype. Similarly, co-infection with endosomolytically active adenoviral
variants resulted in a partial complementation of the mutant phenotype. Contrarily, endosomolytically
inactive adenoviral variants, as well as wild-type EC carrying sequestered VP1uR sequences, were
unable to restore infectivity of the PLA2-negative mutants. Thus, the capsid-tethered PLA2 motif seems
to be either directly or indirectly required for successful penetration of the endosomal membranes.
The information regarding the precise site of PtPV endosomal escape is still incomplete. Previous
in vitro experiments showed that the optimal pH for the parvoviral PLA2 enzymatic activity ranges
between pH 6 to 7, but this activity drastically decreases at a pH below 5 [99]. Correspondingly,
the acidic lysosomal environment would not provide optimal conditions for PLA2-mediated escape
from the degradative pathway. Therefore, it is tempting to speculate that only a subset of incoming
viruses manages to escape the endocytic route from a pre-lysosomal compartment in the absence of
vesicle disintegration. This hypothesis is supported by the fact that MVM externalizes VP1-Nt already
within the first minutes of infection, thus exposing the functional PLA2 enzymatic activity on its surface.
Additionally, brefeldin A, an antibiotic blocking the transition between early and late endosomes has
been demonstrated to abrogate MVM infection [68]. In summary, these results collectively suggest that
a minority of virions that enter the cytosol escape from an intermediate pre-lysosomal vesicle, namely
late endosomes [67].
Finally, it should be emphasized that understanding the infectious pathway of parvoviruses is
complicated by the fact that the bulk of incoming particles are retained within lysosomal compartments
following a degradative route. This phenomenon may largely account for the high particle-to-infection
ratio found in most parvovirus–cell systems. Moreover, the lack of dynamic information in IF
or EM experiments has complicated the study of virus trafficking through the highly dynamic
and overlapping vesicular endocytic pathway. Emerging advances in time-lapse microscopy may
render live-cell imaging an important complementary method to study the complex nature of PtPV
endosomal trafficking.
6. Trafficking and Interactions in the Cytosol
Transport and maturation of incoming PtPV particles inside endosomes is not only required
for endosomal escape, but also to confer transport and nuclear targeting capacity to the capsids in
the cytoplasm. Capsids directly microinjected into the cytoplasm, bypassing endosomal maturation,
remain immobile and fail to enter the nucleus [69,100]. However, capsid modifications continue also
after endosomal escape. In general, it is difficult to examine PtPV capsids after endosomal escape,
as most of the incoming capsids are retained in the endosomal pathway for many hours after uptake
and do not actually contribute to the infection, Figure 3. The inefficient escape from endocytic vesicles
represent a major complication to identify and characterize the particles that, following the infectious
pathway, have reached the cytosol and target the nucleus for replication.
6.1. Interactions with the Cell Cytoskeleton and Motor Proteins
Following their release into the cytosol, the incoming viral particles are transported to the
perinuclear area and enter the nucleus for replication. Cytoplasmic components and the intricate
cytoskeleton network (microtubules (MTs), actin and intermediate filament) create a viscous cytosolic
environment, with an average pore size of 20–40 nm [101]. These physical properties of the cytoplasm
restrict the free diffusion of particles larger than 500 kDa or above 25 nm diameter [53,102–105].
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The diameter of the parvovirus particle is close to the size limit that prohibits passive diffusion.
Therefore, the efficient movement of parvovirus particles across the cytoplasm towards the nuclear
vicinity is expected to mostly depend on microtubules and their associated motor proteins.
MTs are polarized structures with a plus end toward the cell periphery and a minus end
toward the MT organizing center (MTOC) in the nuclear vicinity. Several studies have shown that
PtPV infection requires intact MTs [42,68,69,79,106,107]. CPV has been demonstrated to depend on
active, dynein-mediated retrograde transport along the MT. Nocodazole (ND), a highly specific drug
promoting tubulin depolymerization in mammalian cells, prevented nuclear translocation of CPV.
Similarly, an antibody against the intermediate chain of the motor protein dynein also reduced the
nuclear accumulation of CPV capsids. EM based studies and co-immunoprecipitation (IP) of CPV
with the intermediate chain of dynein supported a dynein-mediated transport of CPV along the
microtubules toward the nucleus [79,106,107]. Similar observations were reported for MVM, where
disruption of MT and actin filaments substantially reduced the infection [68].
Therefore, PtPV particles require the cytoskeleton and associated motor proteins to assist their
transport to the nucleus. However, it is unclear whether the cytoskeleton is required to maintain
the movement of the virus-containing endosomal vesicles or if a direct interaction of the incoming
particles and cytoskeleton components exist in the cytosol. At least for CPV, it has been shown by IP
and IF experiments, that capsids interact directly with dynein, the minus-end directed motor protein
that transports cargo along MTs towards the MTOC near the nucleus [79]. The movement of cellular
cargoes, as well as viruses, along MTs has been shown to be bi-directional and saltatory, involving
cytoplasmic dynein (retrograde transport) and kinesin (anterograde transport) [108]. Accordingly,
the association of incoming parvovirus particles with kinesin can be expected. Although not well
understood, the net direction toward the nucleus is achieved during entry.
Apart from MTs and actin, the intermediate filament network (IFN) also plays an important role
during viral infections [109]. The IFN protein vimentin is required by the incoming MVM particles
during the endocytic trafficking and after endosomal escape in order to reach the perinuclear area.
MVM infection induces the re-distribution of vimentin to perinuclear regions and MVM replication is
reduced in cells without a functional vimentin IFN [110].
Collectively, these studies suggest that the cytoplasmic trafficking of PtPV capsids depends on the
cell cytoskeleton, notably the MTs and associated motor proteins. However, the role of the cytoskeleton
is not limited to the entry step but has been also implicated in late stages of the infection during virus
egress. MVM transport from the nucleus to the cell periphery is associated with the degradation
of actin fibers and the stabilization of microtubules [111]. Given the importance of MTs in many
cellular processes and pathological disorders, including cancer, a thorough knowledge of the dynamic
interactions of PtPV with the host cell transport machinery will be useful to better understand their
infection mechanism and oncolytic properties.
6.2. Interactions with the Ubiquitin-Proteasome Machinery
The proteasome is a large multisubunit complex that selectively degrades ubiquitinated proteins.
It is involved in a wide variety of proteolytically mediated intracellular processes, such as cell
cycle progression, apoptosis, metabolic regulation and transcriptional control. The proteasome is
also involved in the processing of antigens, generating peptides for the major histocompatibility
complex pathway [112], and viruses from different families require proteasome activities in order to
infect [113]. The ubiquitin-proteasome may also play important roles during PtPV entry, but current
accumulated evidence is still mostly indirect. For example, although MVM and CPV capsids are not
ubiquitinated during entry, these viruses, as well as PPV, require the activity of the proteasome for
the infection [109]. In the presence of proteasome inhibitors, MVM capsids accumulate and persist
in lysosomes and the infection is inhibited [68,114]. Since the proteasome control multiple biological
processes, the identification of the specific step(s) of the PtPV infection where the proteasome activity
is important, will be challenging.
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6.3. Other Interactions in the Cytoplasm
Sumoylation is a post-translational modification analogous to ubiquitination, which involves
addition of small ubiquitin-like modifiers (SUMOs). Sumoylation can affect protein stability, subcellular
localization and protein–protein interactions. Putative roles of SUMO-PtPV interactions in entry are
unknown, and therefore constitute promising issues for research.
Other cytoplasmic interactions, occurring during PtPV entry, may provoke cytotoxic effects
associated with the successful infection. For example, the direct interaction of CPV with mitochondria
during entry causes depolarization of the mitochondrial transmembrane potential and the induction
of oxidative stress. These effects activate cell survival signaling through the ERK1/2 cascade and cell
death [115].
7. Nuclear Entry and Uncoating
PtPV, as most DNA viruses, replicate within the cell nucleus making extensive use of the
transcription and replication machineries of the host cells. PtPV structural proteins enter the nucleus at
two stages of the PtPV life cycle; early in the infection, when the incoming virion delivers its genome
for replication, and later when the newly expressed viral structural subunits are imported into the
nucleus as assembly intermediates [16,116]. Macromolecules can translocate bi-directionally through
the nuclear pore complex (NPC) via either passive or facilitated processes. While passive diffusion is
related to ions and small to middle-size molecules, facilitated diffusion is a highly selective process
mainly mediated by nuclear localization signals (NLS) exposed on the cargo molecules and recognized
by specialized transport proteins [117,118]. The NPC has a functional diameter up to a maximum
of 39 nm [119]. Larger macromolecules may still be translocated across the NPC, but must undergo
rearrangements to reduce their diameter [118]. The functional diameter of the NPC central channel is
in the range of the diameter of the parvovirus capsids. Therefore, unlike larger viruses, which partially
or completely uncoat prior translocation through the NPC [120], the incoming parvovirus particle
could pass through without disassembly.
Two distinct mechanisms have been proposed for the nuclear entry of incoming PtPV. The first
body of data suggests that PtPV particles translocate across the NPC mediated by exposed NLS
in the VP1 unique region (VP1uR). As mentioned above, PtPV undergo structural rearrangements
triggered by the acidic conditions inside endosomes, resulting in the exposure of VP1uR. Cytoplasmic
microinjection of VP1uR-specific antibodies was able to neutralize CPV infection [107]. Besides the
PLA2 motif, which is required for endosomal escape (see above), VP1uR contains clusters of basic
amino acids (BC) resembling classical NLS [9,121,122]. The BC1 sequence corresponds to a classical
NLS, which commonly bind α and/or β importin receptors to translocate cargo across the NPC [123],
and it was required for the nuclear translocation of newly synthesized VP1 subunits and VP1/VP2
complexes of MVM devoid of the VP2 nuclear transport motif [124]. Mutations in other BC sequences
of VP1uR affected nuclear import of viral proteins and the infection, suggesting that they function in
concert to facilitate the nuclear targeting of PtPV [9,122]. Accordingly, these data strongly suggest that
the incoming PtPVs recruit the cellular import machinery to translocate across the NPC.
Other studies suggest a disparate NPC-independent nuclear entry following local disintegration of
the nuclear membrane [125]. When microinjected into the cytoplasm of Xenopus oocytes, MVM was able
to cause local nuclear envelope breakdown (NEB) in a time- and concentration-dependent manner [126].
It has been proposed that MVM hijacks a cellular pathway to disrupt the nuclear envelope of the host
cell. The exact mechanism is not well understood, but appears to involve the re-localization of caspase 3
from the cytoplasm to the nucleus without its activation above basal levels in MVM infected cells.
In the nucleus, caspase 3 cleaves lamin B2, resulting in a sustained disruption of the nuclear lamina
structure and progression of nuclear envelope rupture. MVM-mediated, non-apoptotic caspase 3
activity induces nuclear entry of MVM capsids and possibly the nuclear targeting of further accessory
proteins required for replication. Inhibition of caspase 3 during MVM infection resulted in a significant
reduction of nuclear entry of MVM capsids and delayed expression of early viral gene products [127],
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hence the sequential molecular events leading to NEB were elucidated. The initial interaction of
incoming capsids with NPC proteins would cause capsid structural rearrangements, which initiate
a signal cascade resulting in local nuclear envelope disintegration. It was shown that calcium-mediated
activation of Protein Kinase C (PKC) is essential for NEB, which together with caspase 3, triggers
activation of the kinase cdk-2, a critical element governing the structure of the nuclear envelope [128].
These apparently contradictory observations may function in concert to promote PtPV nuclear entry.
An initial docking of the PtPV capsids to the NPC could trigger a local disintegration of the nuclear
envelope, which would facilitate the transport of the capsids across the NPC.
Finally, the mechanism and intracellular site of PtPV uncoating is not well understood. There are
indications that PtPV capsids remain assembled in the cytosol and enter the nucleus intact. For example,
CPV infectivity can be blocked by injecting neutralizing antibodies against intact capsids in the cytosol
and nucleus, respectively [106]. The requirement of a complete disassembly to release PtPV DNA
seems unlikely, and the viral DNA is more likely extruded from intact capsids. In vitro, the viral
ssDNA can be externalized by a variety of treatments, which do not cause capsid disintegration,
and the 3′ terminal hairpin can act as template for the DNA polymerase [76,77,114]. During the
uncoating process, the viral DNA is thought to pass through the five-fold axis pore of the capsid [129].
These findings suggest that the partially exposed viral DNA within the nucleus can be used as template
for initiating DNA replication by the host cell DNA polymerase, whereby the remaining internal DNA
can be completely pulled out without the need to disassemble the stable PtPV capsid. However,
the exact time of uncoating (prior, during or after entry into the nucleus) remains a matter of debate.
IF experiments, either with fluorescently labeled virus or with conformational antibodies against
assembled particles, have shown that the capsid enters the nucleus intact, although other authors
have shown that viruses enter the nucleus after partial or total disassembly in the cytosol or NPC.
The difficulties in discriminating between the infectious and the non-infectious routes could explain
these contradictory observations.
8. Conclusions and Outlook
This review was intended to update and summarize our current knowledge on the traffic of the
Protoparvovirus infectious particle from the host cell plasma membrane to the nucleus. The study of this
process is complex, because PtPV can use various pathways when infecting a cell, each one consisting
of a number of steps, and each step may involve a series of specific and sequential interactions. Figure 4
illustrates the best experimentally supported pathways and their major regulatory mechanisms.
Increasing the level of complexity is the fact that PtPV–host interactions are dynamic,
and moreover, many of those interactions are actually irrelevant for productive infection. Therefore,
many unresolved questions will need to be addressed in the future in order to achieve a comprehensive
understanding of PtPV entry. Major steps of the PtPV entry requiring detailed study should include
the role of co-receptors, the precise mechanism underlying endosomal escape, the structures and paths
involved in nuclear entry, specific triggers and the site where the PtPV genome becomes accessible for
replication. The complexity of these tasks demands the improvement of the current technology and
the implementation of novel methods, such as the combination of single-virus tracking in living cells
with high-resolution imaging technologies or large-scale RNAi screening. A better knowledge of the
intricate process of PtPV entry will be fundamental, not only to better understand the tropism, host
range and pathogenesis of the infections cause by pathogenic PtPVs, but also to improve and expand
the application of non-pathogenic rodent parvoviruses in cancer therapy.
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Figure 4. Model of PtPV cell entry and nuclear import. In the productive infection, PtPV capsids
bind to one or more cell receptors (1). Following lateral diffusion, capsids are captured by pre-formed
or forming clathrin pits (2). Or otherwise become detached from their receptors (3). Capsids are
internalized via clathrin-mediated endocytosis (4) and enter the endocytic pathway where the low pH
environment and local enzymes trigger structural rearrangements (5). Major structural changes
are de novo VP2-Nt exposure and cleavage and particle dephosphorylation, leading to VP1-Nt
(or VP1uR) exposure through the channel. The endosomal trafficking may vary in complexity and
time, but commonly only a small proportion of particles escape after altering the endosomal membrane
through the activity of the VP1-encoded phospholipase A2 (6). Many incoming infectious particles fail
to escape from endosomes and are routed to and accumulated in the degradative lysosomes (7). In the
cytosol, PtPV exploit the cytoskeleton and motor proteins to move to the nuclear vicinity (8). It is not
yet clear how the viruses and/or their genomes enter the nucleus, as nuclear pore-dependent entry
and permeabilization of the nuclear envelope have been proposed (9). The site and timing of capsid
uncoating are also uncertain processes. Growing evidences suggest that capsids remain assembled in
the cytosol and enter the nucleus intact, and the uncoating would take place during the interaction
with NPC proteins and/or following nuclear entry (10).
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